CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M

CorMedix Inc.

Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.
Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.
Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.
Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.
Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029.

item 1.01 item 2.02 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.